TP53 and Ascites: Specifically, the in vitro and in vivo application of Ad-p53 resulted in the activation of apoptosis and taxol-sensitisation in ovarian cancer cells [38], while Gendicine, a gene therapy product approved for clinical use by the Chinese FDA in 2003, is now demonstrating very promising results, leading to a 90% patient response rate and 100% peritoneal effusion resolution [37].